S&P 500   3,236.92 (-2.37%)
DOW   26,763.13 (-1.92%)
QQQ   264.16 (-3.05%)
AAPL   107.12 (-4.19%)
MSFT   200.59 (-3.29%)
FB   249.02 (-2.25%)
GOOGL   1,409.39 (-3.45%)
AMZN   2,999.86 (-4.13%)
NVDA   484.95 (-4.07%)
TSLA   380.36 (-10.34%)
BABA   272.95 (-0.85%)
CGC   14.60 (-8.98%)
GE   6.11 (-2.24%)
MU   49.85 (+0.30%)
AMD   74.73 (-3.82%)
T   27.87 (-2.24%)
F   6.64 (-2.06%)
ACB   5.17 (-29.37%)
GILD   63.09 (-0.49%)
NFLX   470.61 (-4.19%)
DIS   123.28 (-3.09%)
BAC   23.26 (-2.84%)
BA   151.18 (-3.58%)
S&P 500   3,236.92 (-2.37%)
DOW   26,763.13 (-1.92%)
QQQ   264.16 (-3.05%)
AAPL   107.12 (-4.19%)
MSFT   200.59 (-3.29%)
FB   249.02 (-2.25%)
GOOGL   1,409.39 (-3.45%)
AMZN   2,999.86 (-4.13%)
NVDA   484.95 (-4.07%)
TSLA   380.36 (-10.34%)
BABA   272.95 (-0.85%)
CGC   14.60 (-8.98%)
GE   6.11 (-2.24%)
MU   49.85 (+0.30%)
AMD   74.73 (-3.82%)
T   27.87 (-2.24%)
F   6.64 (-2.06%)
ACB   5.17 (-29.37%)
GILD   63.09 (-0.49%)
NFLX   470.61 (-4.19%)
DIS   123.28 (-3.09%)
BAC   23.26 (-2.84%)
BA   151.18 (-3.58%)
S&P 500   3,236.92 (-2.37%)
DOW   26,763.13 (-1.92%)
QQQ   264.16 (-3.05%)
AAPL   107.12 (-4.19%)
MSFT   200.59 (-3.29%)
FB   249.02 (-2.25%)
GOOGL   1,409.39 (-3.45%)
AMZN   2,999.86 (-4.13%)
NVDA   484.95 (-4.07%)
TSLA   380.36 (-10.34%)
BABA   272.95 (-0.85%)
CGC   14.60 (-8.98%)
GE   6.11 (-2.24%)
MU   49.85 (+0.30%)
AMD   74.73 (-3.82%)
T   27.87 (-2.24%)
F   6.64 (-2.06%)
ACB   5.17 (-29.37%)
GILD   63.09 (-0.49%)
NFLX   470.61 (-4.19%)
DIS   123.28 (-3.09%)
BAC   23.26 (-2.84%)
BA   151.18 (-3.58%)
S&P 500   3,236.92 (-2.37%)
DOW   26,763.13 (-1.92%)
QQQ   264.16 (-3.05%)
AAPL   107.12 (-4.19%)
MSFT   200.59 (-3.29%)
FB   249.02 (-2.25%)
GOOGL   1,409.39 (-3.45%)
AMZN   2,999.86 (-4.13%)
NVDA   484.95 (-4.07%)
TSLA   380.36 (-10.34%)
BABA   272.95 (-0.85%)
CGC   14.60 (-8.98%)
GE   6.11 (-2.24%)
MU   49.85 (+0.30%)
AMD   74.73 (-3.82%)
T   27.87 (-2.24%)
F   6.64 (-2.06%)
ACB   5.17 (-29.37%)
GILD   63.09 (-0.49%)
NFLX   470.61 (-4.19%)
DIS   123.28 (-3.09%)
BAC   23.26 (-2.84%)
BA   151.18 (-3.58%)
Log in
NASDAQ:ARCT

Arcturus Therapeutics Stock Forecast, Price & News

$38.95
-2.18 (-5.30 %)
(As of 09/23/2020 04:30 PM ET)
Add
Compare
Today's Range
$38.85
Now: $38.95
$42.81
50-Day Range
$38.26
MA: $48.80
$62.65
52-Week Range
$8.51
Now: $38.95
$66.24
Volume476,050 shs
Average Volume585,667 shs
Market Capitalization$949.91 million
P/E RatioN/A
Dividend YieldN/A
Beta3.11
Arcturus Therapeutics Ltd., an RNA medicines company, focuses on treatment of liver and respiratory diseases. The company's pipeline of RNA therapeutics include programs pursuing rare diseases, hepatitis B, non-alcoholic steatohepatitis, cystic fibrosis, and vaccines. The company owns LUNAR lipid-mediated delivery and Unlocked Nucleomonomer Agent (UNA) technology, including UNA Oligomers, which are covered by its patent portfolio, including 152 patents and patent applications issued in the United States, Europe, Japan, China, and internationally. Its proprietary UNA technology is used to target individual genes in the human genome, as well as viral genes, and other species for therapeutic purposes. The company develops novel RNA therapeutics through its partnerships with Janssen Pharmaceuticals, Inc., Ultragenyx Pharmaceutical, Inc., Takeda Pharmaceutical Company Limited, Synthetic Genomics Inc., CureVac AG, and Cystic Fibrosis Foundation Therapeutics Inc. The company was founded in 2013 and is headquartered in San Diego, California.
Read More
Arcturus Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.4Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.75 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ARCT
CUSIPN/A
Phone858-900-2660

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$20.79 million
Book Value$1.27 per share

Profitability

Net Income$-25,990,000.00
Net Margins-341.76%

Miscellaneous

Employees72
Market Cap$949.91 million
Next Earnings Date11/5/2020 (Estimated)
OptionableOptionable
$38.95
-2.18 (-5.30 %)
(As of 09/23/2020 04:30 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ARCT News and Ratings via Email

Sign-up to receive the latest news and ratings for ARCT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Arcturus Therapeutics (NASDAQ:ARCT) Frequently Asked Questions

How has Arcturus Therapeutics' stock price been impacted by COVID-19?

Arcturus Therapeutics' stock was trading at $13.09 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ARCT shares have increased by 197.6% and is now trading at $38.95.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Arcturus Therapeutics?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcturus Therapeutics in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Arcturus Therapeutics
.

When is Arcturus Therapeutics' next earnings date?

Arcturus Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Arcturus Therapeutics
.

How were Arcturus Therapeutics' earnings last quarter?

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) announced its quarterly earnings data on Monday, August, 10th. The biotechnology company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.53) by $0.02. The biotechnology company earned $2.32 million during the quarter, compared to analyst estimates of $5.08 million. Arcturus Therapeutics had a negative net margin of 341.76% and a negative return on equity of 409.05%.
View Arcturus Therapeutics' earnings history
.

What price target have analysts set for ARCT?

9 brokerages have issued twelve-month price objectives for Arcturus Therapeutics' stock. Their forecasts range from $19.00 to $82.00. On average, they anticipate Arcturus Therapeutics' stock price to reach $55.22 in the next twelve months. This suggests a possible upside of 41.8% from the stock's current price.
View analysts' price targets for Arcturus Therapeutics
.

Who are some of Arcturus Therapeutics' key competitors?

What other stocks do shareholders of Arcturus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcturus Therapeutics investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Novavax (NVAX), Dynavax Technologies (DVAX), NVIDIA (NVDA), Opko Health (OPK), Pfizer (PFE), Abbott Laboratories (ABT), Crispr Therapeutics (CRSP) and Square (SQ).

Who are Arcturus Therapeutics' key executives?

Arcturus Therapeutics' management team includes the following people:
  • Mr. Joseph E. Payne M.Sc., Founder, Pres, CEO & Director (Age 47)
  • Dr. Padmanabh Chivukula, Founder, Chief Scientific Officer, COO & Sec. (Age 40)
  • Mr. Andrew H. Sassine, CFO & Director (Age 55)
  • Mr. Kevin T. Skol, Sr. VP of Bus. Devel. & Alliance Management
  • Keith C. Kummerfeld CPA, VP of Fin. & Corp. Controller

What is Arcturus Therapeutics' stock symbol?

Arcturus Therapeutics trades on the NASDAQ under the ticker symbol "ARCT."

Who are Arcturus Therapeutics' major shareholders?

Arcturus Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (3.57%), Cormorant Asset Management LP (3.28%), FMR LLC (2.77%), Federated Hermes Inc. (2.98%), Orbimed Advisors LLC (0.98%) and Point72 Asset Management L.P. (0.91%). Company insiders that own Arcturus Therapeutics stock include Andy Sassine, Joseph E Payne, Keith C Kummerfeld, Magda Marquet, Pad Chivukula and Peter C Farrell.
View institutional ownership trends for Arcturus Therapeutics
.

Which institutional investors are selling Arcturus Therapeutics stock?

ARCT stock was sold by a variety of institutional investors in the last quarter, including Dfpg Investments LLC, Sumitomo Mitsui Trust Holdings Inc., Bank of Montreal Can, Creative Planning, Engineers Gate Manager LP, and Bank of America Corp DE.
View insider buying and selling activity for Arcturus Therapeutics
.

Which institutional investors are buying Arcturus Therapeutics stock?

ARCT stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Federated Hermes Inc., Cormorant Asset Management LP, FMR LLC, Orbimed Advisors LLC, Point72 Asset Management L.P., Jennison Associates LLC, and Candriam Luxembourg S.C.A.. Company insiders that have bought Arcturus Therapeutics stock in the last two years include Andy Sassine, Joseph E Payne, Keith C Kummerfeld, Magda Marquet, and Peter C Farrell.
View insider buying and selling activity for Arcturus Therapeutics
.

How do I buy shares of Arcturus Therapeutics?

Shares of ARCT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Arcturus Therapeutics' stock price today?

One share of ARCT stock can currently be purchased for approximately $38.95.

How big of a company is Arcturus Therapeutics?

Arcturus Therapeutics has a market capitalization of $949.91 million and generates $20.79 million in revenue each year. The biotechnology company earns $-25,990,000.00 in net income (profit) each year or ($2.15) on an earnings per share basis. Arcturus Therapeutics employs 72 workers across the globe.

What is Arcturus Therapeutics' official website?

The official website for Arcturus Therapeutics is www.arcturusrx.com.

How can I contact Arcturus Therapeutics?

Arcturus Therapeutics' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-900-2660 or via email at [email protected]

This page was last updated on 9/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.